Hexagon Nutrition Q1 FY27: Strong revenue growth, but margins softened

Hexagon Nutrition opened FY27 with a sharp jump in scale. Consolidated revenue from operations for Q1 FY27 rose to INR 104.31 crore from INR 72.86 crore in Q1 FY26, a year-on-year increase of 43.16%. EBITDA came in at INR 11.80 crore and profit after tax (PAT) was INR 8.07 crore.

The headline growth was strong, but profitability ratios moved the other way. EBITDA margin declined to 11.31% from 13.81% in Q1 FY26, while PAT margin moderated to 7.74% from 8.86%. The quarter therefore highlighted a familiar trade-off for a scaling nutrition manufacturer: volume growth is visible, but sustaining margins depends on product mix, operating leverage, and capacity utilisation.

A diversified nutrition platform with three engines

Hexagon positions itself as an integrated nutrition company spanning micronutrient premixes, therapeutic and humanitarian nutrition products, and branded clinical and wellness nutrition. Management reiterated this structure in its maiden earnings call for FY26, describing how the portfolio serves FMCG and pharma customers (premixes), institutional and UN-linked programs (therapeutic foods and micronutrient powders), and hospitals and consumers (clinical and wellness nutrition).

In the FY26 call, the company disclosed an approximate revenue mix: branded business around 30%, premix segment around 35% to 40%, and ESG around 30%. While the company did not publish segment EBITDA or PAT splits, it did share indicative gross margin bands by segment, with branded products at 60% to 68%, premixes at 35% to 40%, and ESG at 25% to 30%. This mix matters because increasing the branded contribution can materially change consolidated profitability over time.

Financial summary (consolidated)

Capacity utilisation remains the operational lever

The company’s investor presentation provides plant-wise capacity and utilisation for FY26 and the picture is mixed. The Nashik facility, which is described as the flagship multi-product plant, reported high utilisation in dry premix at 95.2% and clinical at 56.0%. However, other units operated at materially lower levels in FY26. The Chennai SEZ plant reported dry utilisation of 30.1% and liquid utilisation of 4.8%, with MNP utilisation at 16.6%. The Thoothukudi SEZ facility for RUTF/RUSF reported utilisation of 18.9%, while the Uzbekistan plant showed dry premix utilisation of 3.3% and MNP utilisation of 22.9%.

Management addressed these concerns directly in the FY26 call, explaining that the headline utilisation is a blended number across segments and plants. The company stated that branded operations run around 50% to 60% utilisation, premix around 40% to 45%, while ESG varies with tender and order flows. It also indicated that blended utilisation could move toward 35% to 40% as growth continues.

This matters because the presentation explicitly links margin improvement to manufacturing efficiency and operating leverage, and sets a medium-term target of 15% plus EBITDA margin. Reaching that level, based on the information provided, would likely require higher utilisation in underused facilities along with a more favorable revenue mix.

Branded growth strategy: widening doctor-led reach and online channels

Hexagon’s branded portfolio includes Pentasure in adult clinical nutrition, Pediagold in pediatric nutrition, and Obesigo in weight management, along with Nutrone for everyday nutrition. During the earnings call, investors noted that Pentasure appears to have stronger recall and doctor recommendation, while Pediagold and Obesigo have lower penetration.

Management acknowledged this and said it intends to increase focus on Pediagold and Obesigo, while also expanding beyond Tier 1 markets. The company described its approach as expanding its medical representative network, widening distribution, increasing presence across e-commerce platforms and e-pharmacies, and supporting these efforts with medical marketing, conferences, and continuing education programs.

The rationale is clear in the margin profile management shared. With branded gross margins indicated at 60% to 68%, even a moderate shift in revenue mix toward branded products can lift profitability, provided growth is achieved without disproportionate increases in selling costs.

Exports and sourcing: diversification is the stated risk mitigant

Exports are a meaningful part of the business. In the FY26 call, a participant referenced the company’s disclosure that 57% of revenues come through exports and asked for more detail. Management responded that over 80% of export revenue comes from premixes and ESG, with the balance from branded exports.

Geopolitical disruptions were raised in the context of the West Asia war situation. Management stated that West Asia is less than 20% of exports and that the company’s export book is diversified by geography. It also suggested that nutrition ingredients remain essential procurement for countries even during disruptions.

On raw materials, management said imports are under 25% of total requirements and that sourcing spans China, Singapore, Korea and Europe. It mentioned imported vitamins such as Vitamin A, B-group vitamins, Vitamin C and folic acid, and noted that the company uses strategic inventory for certain inputs. In branded products, it stated it can pass on cost increases to consumers through price changes when required, citing whey price volatility as an example.

What stands out from the quarter

Q1 FY27 showcased strong top-line expansion, but the company will likely be judged on two execution questions it has itself highlighted: improving utilisation across low-loaded plants, and scaling branded revenues to improve mix and margins.

The company’s narrative is supported by a wide product footprint and a global customer base, but the presentation data shows that several assets are operating far below capacity. If demand visibility improves, especially in tender-driven ESG products and in export premixes, operating leverage could become a meaningful earnings driver. At the same time, the branded strategy depends on sustained doctor-led adoption and distribution scale-up, where competition from larger clinical nutrition players remains intense.

For investors tracking the story, the central theme is simple: growth is already visible, but the next phase hinges on converting that scale into steadier margins through utilisation and mix.